We offer the purest vorinostat (rINN) (or suberoylanilide
hydroxamic acid (SAHA)) product as a critical element in
cancer targeted drugs for the treatment of cutaneous T
cell lymphoma (CTCL), a type of skin cancer. It also has
been proven capable of removing latent HIV virus from the
patient's body. It was approved by the US FDA in 2006.

The pivotal component for a FDA approved medicine often
used by children and young adults between 1 and 21 years
old who are suffering from acute lymphoblastic
leukemia (ALL; a type of cancer of the white blood cells)
and relapsed or refractory lymphoblastic leukemia.